Principles of Creation of a Genetic Engineering Construction for Obtaining Humanized Transgenic Mice with <i>HLA-C*07:02:01:01</i>, as a Promote of Innovative Transgenic and Knockout Biomodels-Reference-Cited by-同舟云学术

Principles of Creation of a Genetic Engineering Construction for Obtaining Humanized Transgenic Mice with <i>HLA-C*07:02:01:01</i>, as a Promote of Innovative Transgenic and Knockout Biomodels

Published:2024-04-05 Issue:1 Volume:20 Page:8-20
ISSN:2713-0428
Container-title:Journal Biomed
language:
Short-container-title:BIOMEDICINE

Author:

Karkischenko N. N.¹,Lazarev V. N.²,Manuvera V. A.²,Bobrovsky P. A.²,Petrova N. V.¹,Koloskova E. M.³,Glotova E. S.¹

Affiliation:

1. Scientific Center of Biomedical Technologies of the Federal Medical and Biological Agency of Russia

2. Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine of the Federal Medical and Biological Agency of Russia

3. All-Russian Research Institute of Physiology, Biochemistry and Animal Nutrition — branch of the Federal Scientific Centre of Animal Husbandry — All-Russian Institute of Animal Husbandry named after acad. L.K. Ernst

Abstract

Genetic differences in different populations influence the mechanism and efficacy of drugs. Biomodels that take into account the peculiarities of genetic polymorphism in different individuals allow to more fully investigate the molecular-genetic mechanisms of action of pharmacological agents, including immunobiological ones. Recombinant DNA encoding a hybrid MHC class I protein containing human ß2-microglobulin fused with antigen-presenting domains (α1 and α2 domains) of the HLA-C*07:02:01:01 molecule and α3 domain of the mouse H2-complex was created. The purified linearized DNA fragment containing the target construct flanked by regulatory fragments ensuring its stable transcription was used to obtain a new line of humanized transgenic mice. The principles of designing humanized transgenic mice by encoding a chimeric MHC class I protein containing antigen-presenting domains HLA-C*07:02:01:01 are similar to those for obtaining mice of the HLA-А*02:01:01 and HLA-B*18:01:01:02 humanized transgenic lines. These transgenic lines of laboratory mice are independent biomodels, and also be used as baselines for obtaining corresponding transgenic and knockout lines.

Publisher

Scientific Center for Biomedical Technologies of the Federal Medical-Biological Agency

Reference24 articles.

1. Zubkova O.V., Ozharovskaya T.A., Dolzhikova I.V., Popova O., Shcheblyakov D.V. Grousova D.M., Dzharullayeva A.Sh., Tukhvatulin A.I., Tukhvatulina N.M., Shcherbinin D.N., Esmagambetov I.B., Tokarskaya E.A., Botikov A.G., Erokhova A.S., Izhaeva F.M., Semikhin A.S., Borisevich S.V., Naroditsky B.S., Logunov D.Yu., Ginzburg A.L. Pharmacevticheskoe sredstvo I sposob ego ispolzovania dlya indukcii specificheskogo immuniteta protiv virusa tyazhelogo ostrogo respiratornogo sindroma SARS-CoV-2 (variantyi) [A pharmaceutical product and a method of its use for the induction of specific immunity against the SARS-CoV-2 severe acute respiratory syndrome virus (variants)]. Patent RU No. 2731342 C1, 2020. (In Russian).

2. Karkischenko V.N., Bolotskikh L.A., Kapanadze G.D., Karkischenko N.N., Koloskova E.M., Maksimenko S.V., Matveyenko E.L., Petrova N.V., Ryabykh V.P., Revyakin A.O., Stankova N.V., Semenov Kh.Kh. Sozdaniye liniy transgennykh zhivotnykh-modeley s genami cheloveka NAT1 i NAT2 [Creation of lines of transgenic animal models with human genes NAT1 and NAT2]. Biomeditsina [Journal Biomed]. 2016;1:74–84. (In Russian).

3. Karkischenko V.N., Petrova N.V., Savchenko E.S., Ogneva N.S., Koloskova E.M., Maksimenko S.V., Manuvera V.A., Bobrovsky P.A., Lazarev V.N. Sozdanie polnih gibritnih DNKkonstrukcij s genom cheloveka HLA-A*02:01:01:01 [Chimeric Construct Engineering with Human Variant HLA-A*02:01:01:01]. Biomeditsina [Journal Biomed]. 2021;17(1):10–23. (In Russian).

4. Karkischenko V.N., Ryabykh V.P., Karkischenko N.N., Dulya M.S., Ezerskiy V.A., Koloskova E.M., Lazarev V.N., Maksimenko S.V., Petrova N.V., Stolyarova V.N., Trubitsyna T.P. Molekulyarno-geneticheskie aspekty tekhnologii polucheniya transgennykh myshej s integrirovannymi genami N-atsetiltransferazy (NAT1 i NAT2) cheloveka [Molecular and genetic aspects of the technology for producing transgenic mice with integrated genes of human N-acetyltransferase (NAT1 and NAT2)]. Biomeditsina [Journal Biomed]. 2016;1:4–17. (In Russian).

5. Karkischenko N.N., Glotova E.S., Petrova N.V., Slobodenyuk V.V., Laryushina N.A., Petrov D.V., Vasil’eva I.A. Deryabin K.E. Geneticheskij skrining novoj transgennoj gymanizirovannoj po HLA-A*02:01:01:01 i hβ2m linii myshey [Genetic screening of a new transgenic mouse line humanized for HLA-A*02:01:01:01 and hβ2m]. Biomeditsina [Journal Biomed]. 2023;19(3Е):10–24. (In Russian).

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Increasing, the Specificity of Polyclonal Antibodies to Human and Mouse β2-Microglobulin as an Alternative to the Use of Monoclonal Antibodies in Immunological Analysis;Journal Biomed;2024-07-23

2. Immune Response in HLA-A*02:01 Transgenic Humanized Mice to the Introduction of Horse IgG Antigen;Journal Biomed;2024-07-23

3. Evidence for the Presence of β2m hom Target Proteins and HLA in Humanized Transgenic Mice of HLA-A*02:01, HLA-B*07:02, and HLA-C*07:02 Lines;Journal Biomed;2024-07-23

4. Preparation of Differentiated Recombinant Human β2-Microglobulin and Mouse β2-Microglobulin Proteins for its Detection in Class I HLA Chimeric Molecules;Journal Biomed;2024-07-23

5. Evidence of Trangency and Humanization in Mice Obtained at the SCBMT of FMBA of Russia by Sanger Sequencing Method;Journal Biomed;2024-07-22